SRPT Sarepta Therapeutics Inc

Price (delayed)

$122.69

Market cap

$10.79B

P/E Ratio

N/A

Dividend/share

N/A

EPS

-$8.03

Enterprise value

$11.43B

Sarepta Therapeutics, Inc. is a medical research and drug development company with corporate offices and research facilities in Cambridge, Massachusetts, United States. Incorporated in 1980 as AntiVirals, shortly before going ...

Highlights
The revenue rose by 33% YoY and by 7% QoQ
SRPT's gross profit is up by 31% year-on-year and by 8% since the previous quarter
The EPS has plunged by 56% YoY but it has grown by 2.3% from the previous quarter
The net income has shrunk by 68% YoY
The company's equity has shrunk by 59% YoY and by 11% QoQ

Key stats

What are the main financial stats of SRPT
Market
Shares outstanding
87.98M
Market cap
$10.79B
Enterprise value
$11.43B
Valuations
Price to earnings (P/E)
N/A
Price to book (P/B)
27.98
Price to sales (P/S)
11.51
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
12.25
Earnings
Revenue
$933.01M
EBIT
-$689.96M
EBITDA
-$635.36M
Free cash flow
-$356.17M
Per share
EPS
-$8.03
Free cash flow per share
-$4.07
Book value per share
$4.39
Revenue per share
$10.66
TBVPS
$35.64
Balance sheet
Total assets
$3.13B
Total liabilities
$2.74B
Debt
$1.6B
Equity
$384.95M
Working capital
$1.94B
Liquidity
Debt to equity
4.16
Current ratio
4.13
Quick ratio
3.56
Net debt/EBITDA
-1
Margins
EBITDA margin
-68.1%
Gross margin
85%
Net margin
-75.4%
Operating margin
-57.5%
Efficiency
Return on assets
-22.8%
Return on equity
-117.3%
Return on invested capital
-24.2%
Return on capital employed
-27.5%
Return on sales
-73.9%
Dividend
Dividend yield
N/A
DPS
N/A
Payout ratio
N/A

SRPT stock price

How has the Sarepta Therapeutics stock price performed over time
Intraday
-18.03%
1 week
-14.75%
1 month
-1.51%
1 year
55.05%
YTD
-5.32%
QTD
-5.32%

Financial performance

How have Sarepta Therapeutics's revenue and profit performed over time
Revenue
$933.01M
Gross profit
$793.02M
Operating income
-$536.2M
Net income
-$703.49M
Gross margin
85%
Net margin
-75.4%
The net income has shrunk by 68% YoY
The revenue rose by 33% YoY and by 7% QoQ
SRPT's gross profit is up by 31% year-on-year and by 8% since the previous quarter
SRPT's net margin is down by 26% year-on-year but it is up by 8% since the previous quarter

Growth

What is Sarepta Therapeutics's growth rate over time

Valuation

What is Sarepta Therapeutics stock price valuation
P/E
N/A
P/B
27.98
P/S
11.51
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
12.25
The EPS has plunged by 56% YoY but it has grown by 2.3% from the previous quarter
SRPT's P/B is 131% above its 5-year quarterly average of 12.1 and 62% above its last 4 quarters average of 17.3
The company's equity has shrunk by 59% YoY and by 11% QoQ
The P/S is 42% less than the 5-year quarterly average of 19.9 but 15% more than the last 4 quarters average of 10.0
The revenue rose by 33% YoY and by 7% QoQ

Efficiency

How efficient is Sarepta Therapeutics business performance
The return on equity has dropped by 69% year-on-year and by 20% since the previous quarter
The ROA has plunged by 54% YoY
The ROS has contracted by 24% YoY but it has grown by 9% from the previous quarter
Sarepta Therapeutics's ROIC has increased by 15% from the previous quarter but it has decreased by 7% YoY

Dividends

What is SRPT's dividend
DPS
N/A
Dividend yield
N/A
Payout ratio
N/A

There are no recent dividends present for SRPT.

Financial health

How did Sarepta Therapeutics financials performed over time
The total assets is 14% more than the total liabilities
Sarepta Therapeutics's quick ratio has decreased by 29% YoY and by 6% from the previous quarter
The company's current ratio fell by 28% YoY and by 5% QoQ
The company's equity has shrunk by 59% YoY and by 11% QoQ
SRPT's debt is up by 41% year-on-year

All financial data is based on trailing twelve months (TTM) periods - updated quarterly, unless otherwise specified.